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The eye is an ideal target for exploiting the potential of human induced pluripotent stem cell (hiPSC)
technology in order to understand disease pathways and explore novel therapeutic strategies for
inherited retinal disease. The aim of this article is to map the pathway from state-of-the art laboratory-
based discoveries to realising the translational potential of this emerging technique. We describe the
relevance and routes to establishing hiPSCs in selected models of human retinal disease. Additionally, we
deﬁne pathways for applying hiPSC technology in treating currently incurable, progressive and blinding
retinal disease.
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Stem cells have the ability to self-renew and the capacity to
differentiate into other more specialised cell types. Cell potency
describes the general ability of a cell to differentiate into other
cells. During human development, one of the ﬁrst stem cells to
arise is the human embryonic stem cell (hESC) which can be
found in the inner cell mass of the developing embryo. The
embryonic stem cell has the potential to differentiate into cells
from the three germ layers: endoderm, mesoderm and neuro-
ectoderm. Consequently the hESC is described as pluripotent.
Other stem cells emerge later during development which
display a progressively more restricted phenotypic range and
can be considered tissue or organ-speciﬁc. In adults, endogenous
tissue-speciﬁc stem cells are multipotent with a more restricted
differentiation repertoire normally conﬁned to those cells of the
tissue of origin.
James Thomson reported successful isolation and maintenance
of hESCs in 1998 (Thomson et al., 1998). HESCs have an inﬁnite
proliferation capacity and offered the opportunity to provide a
virtually unlimited supply of human cells for clinical translation
research. However, ethical concerns regarding the derivation of
cells from the inner cell mass of developing blastocysts led to a
drive to investigate alternative methods of deriving pluripotent
stem cells (Ramalho-Santos, 2011). The methodology that even-
tually emerged to produce pluripotent stem cells was developed
on the background of several breakthroughs in cell biology. Sir
John Gurdon ﬁrst demonstrated the cloning of an adult frog from
the transfer of adult intestinal cells into an enucleated Xenopus
laevis ovum (Gurdon, 1962). This illustrated that adult cell fate was
not restricted and that under appropriate conditions differenti-
ated somatic cells could be made pluripotent. Similar nuclear
transfer into mammalian cells was more problematic due to the
smaller size of mammalian eggs. Although successful mammalian
nuclear transfer was later demonstrated using embryonic cells
nuclear transfer cloned animals did not develop from differenti-
ated cell nuclei (Cheong et al., 1993; Prather et al., 1989). Wilmut
et al. demonstrated that these difﬁculties could be overcome by
nuclear transfer into early embryos. Using this technique an adult
sheep was cloned by nuclear transfer from an adult sheep mam-
mary gland cell into a day 9 embryo (Wilmut et al., 1997). This
demonstrated that speciﬁc factors exogenously expressed by
developing embryos can return somatic cells to a pluripotent
state. In 2006, Shinya Yamanaka isolated four transcription factors
that when expressed exogenously induced the formation of
pluripotent cells from somatic cells. This was ﬁrst conﬁrmed using
murine and subsequently human somatic cells (Takahashi et al.,
2007; Takahashi and Yamanaka, 2006). The process of gener-
ating pluripotent cells from somatic cells was termed “reprog-
ramming” and the resultant cells were called induced pluripotent
stem cells (iPSCs). iPSCs shared properties with hESCs including
the ability to self-renew and to be differentiated into the three
germ layers.The clinical translation of basic scientiﬁc discoveries to treat-
ments has been made a priority of national funding bodies
worldwide (McLellan, 2003; MRC, 2013). Ophthalmic research has
been at the forefront of the drive for clinical translation. The eye has
several properties that are advantageous as an organ suitable for
regenerative approaches including relative ease of accessibility,
immune privilege and relative isolation from other body systems.
HiPSC technology was developed relatively recently on the foun-
dation research in several ﬁelds of basic science, the technology is
nearing the point of full clinical translation. Recently, hiPSC derived
retinal pigment epithelium (hiPSC-RPE) have been approved for
use in patient safety trials for the treatment of macular degenera-
tion (Cyranoski, 2013). This article aims to provide a background
into the current state of research in this rapidly evolving ﬁeld with a
focus on the cells of the outer retina. We provide a summary for
planning hiPSC studies, describing hurdles to clinical translation as
well as highlighting future directions of research using hiPSC-
derived retinal cells.
2. Basic principles of human somatic cell reprogramming
Complete reprogramming involves the replacement of the tis-
sue speciﬁc donor cell transcription factors with those that will
induce pluripotency. Additionally, reprogramming requires the
epigenetic stabilisation of the new machinery. The original
reprogramming strategies have provided valuable insight into the
mechanisms involved. A variety of different approaches have now
been established to achieve reprogramming since the original
procedures described by Yamanaka and Thomson. However, as our
knowledge has progressed, the criteria for an ideal protocol have
become clearer. The characteristics of an ideal protocol include:
1. Free from Variation
2. Free from Integration
3. Efﬁcient
4. Fast
5. Frugal2.1. Protocols
In the original reprogramming experiments two sets of tran-
scription factors were identiﬁed concurrently but independently by
Yamanaka and colleagues in Kyoto, Japan (Takahashi et al., 2007)
and Thomson in Madison, Wisconsin, USA (Yu et al.,
2007) (Table 1). Both groups used OCT4 and SOX2, but they
included variations in other factors. Yamanaka used KLF4 and c-
MYC whereas Thomson used NANOG and LIN28. The groups both
used retroviral vectors, but whilst Yamanaka and colleagues used
the pMXs plasmid back-bone derived from Moloney murine
leukaemia virus, Thomson used lentiviral vectors. Lentiviral vectors
have the advantage of being able to integrate in non-dividing cells.
Lentiviral mediated insertion is still the most frequently used
Table 1
Transcription factors commonly used in somatic cellular reprogramming.
Transcription factors
for reprogramming
Function
KLF4 A member of the Krüppel-like family of zinc ﬁnger
transcription factors that is involved in cell
proliferation, differentiation and survival.
C-MYC This transcription factor controls the expression of a
multitude of target genes. It is involved in cell
proliferation, apoptosis, and self-renewal. It is activated
by other pathways including the WNT, epidermal
growth factor and sonic hedgehog pathways. C-MYC is
also a potent oncogene implicated in several cancers.
OCT4 This transcription factor forms a complex with SOX2
and DNA. It plays a crucial role in early embryonic
development and is necessary for the maintenance of
embryonic stem cell pluripotency.
SOX2 SOX2 is important in early development and is required
to maintain self-renewal of undifferentiated embryonic
and neural stem cells.
NANOG NANOG is expressed in undifferentiated cells, including
foetal gonadal organs, the inner cell mass and in
embryonic stem cells. NANOG prevents cells in the
inner cell mass from differentiating into extra-
embryonic, endodermal and trophoectodermal
lineages.
LIN28 Protein which binds microRNA and enhances the
translation of insulin like growth factor 2. LIN28 plays a
role in self-renewal of cells.
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commercially available vectors. We discuss the potential merits of
other protocols using relevant paradigms (Table 2).2.2. Variation: fully versus partially reprogrammed
Criteria for reprogramming have varied over time. There is
considerable disagreement as to the relative importance of these
two mechanisms. In some rare circumstances single transcription
factors alone are able to change the fate of cells from one phenotype
to another, but in these cases the change is within the same germ
layer (Davis et al., 1989). In contrast, when the change is between
germ layers, as is the case during production of hiPSCs, several
transcription factors are still required (Takahashi et al., 2007; Yu
et al., 2007).
With the original reprogramming protocols it was essential that
all factors were not only integrated within the somatic cell genome
but also expressed within a relatively narrow stochastic window.
However, transcription factor expression varied due to differences
in the epigenetic state of the insertion sites. This caused marked
variation in the daughter cells. Consequently, only 1 in 10,000 cells
became pluripotent (Hanna et al., 2009). Consequently, manyTable 2
Advantages and disadvantages of available reprogramming methodologies.
Technique Integrative Non-integrative
Biologically active
Methods Lentiviral, Moloney murine
leukaemia virus
Sendai virus, adeno-vir
Advantages Stable, Efﬁcient vectors,
relatively cheap
Integration free
Disadvantages Integrated leading to copy
number variations,
Genetic footprint
Adenovirus is slow and
Biologically active viru
despite several passage
immune reaction if usecolonies had to be maintained in order to identify cells with the
appropriate pluripotent phenotype.
Those cells in which factors are expressed beyond the stochastic
window of fully reprogrammed cells are termed partially reprog-
rammed. These cells hamper pluripotent cell culture by rapidly
colonising plates (Mikkelsen et al., 2008). Partially reprogrammed
cell numbers can however be reduced by feeder free derivation and
culture (Chan et al., 2009). The combination of cell variation and
partially reprogrammed cells prolong pluripotent cell colony
isolation and therefore lead to increased costs for media and labour.
2.3. Integration versus integration free
There are now several procedures that meet the second
requirement in full. A stably integrated drug inducible system has
provided important opportunities to analyse factors that inﬂuence
the speed and efﬁciency of fate change (Wernig et al., 2008).
Notably, colonies were only seen if transgene expression was
induced for 9 days or more, regardless of the duration of transgene
expression. This pattern is similar to that found following primary
infection by retroviral vectors (Brambrink et al., 2008). Surprisingly,
after transgene expression for 9 days the number of colonies
continued to increase until day 25, which is 15 days after with-
drawal of the drug inducement (Wernig et al., 2008).
The use of integrating vectors can be avoided in several ways.
Firstly, non-integrating viral vectors have been used successfully,
including adenovirus, adeno-associated virus and Sendai virus.
However, these vectors are still biologically active and viruses may
remain in cells for several passages.
Reprogramming methodologies which are non-integrative and
not biologically active have become available. An example are DNA
plasmidswhich have been used successfully (Takahashi et al., 2007;
Yu et al., 2007; Lowry et al., 2008; Okita et al., 2008; Stadtfeld et al.,
2008; Fusaki et al., 2009; Zhou and Freed, 2009; Si-Tayeb et al.,
2010; Nakanishi and Otsu, 2012). Plasmids are introduced by
transfection. Although these do not carry any mechanism to pro-
mote integration, there is a theoretical risk that this may occur
through the activity of DNA repair mechanismsmaking it necessary
to ensure that DNA has not been incorporated into chromosomes
before such cells can be used in therapy. Additionally, excisable
systems have been developed after integration (Kaji et al., 2009;
Woltjen et al., 2009; Somers et al., 2010) as well as DNA-free
reprogramming methods such as mRNA, protein and small mole-
cules (Kim et al., 2009; Zhou et al., 2009; Warren et al., 2010; Lin
et al., 2009).
2.4. Efﬁciency
The efﬁciency of reprogramming is inﬂuenced by chromatin
organisation in the treated cell and the speed of the cell cycle.Biologically inactive
us RNA, proteins, minicircle, episomal
Integration free
Not biologically active
Likely to have less variation
inefﬁcient.
ses remain in cells
s with potential for
d for cell replacement
These are all slow and inefﬁcient except
RNA and often requiring multiple transfections
with the same cells.
Labour intensive and therefore costly at present
Fig. 1. Comparison of relative ease of reprogramming efﬁciency to ease of isolation of
donor cell type. Fibroblasts are the most commonly used donor cell. They are amongst
the easiest to prepare for reprogramming as they are relatively easy to access, prop-
agate as a pure population and maintain. Cells such as mesenchymal cells and hepa-
tocytes require more invasive procedures for extraction. Endothelial progenitor cells
and keratinocytes require isolation from blood and skin respectively. Additionally they
require specialised media to propagate effectively (Aasen et al., 2008; Eminli et al.,
2009; Geti et al., 2012).
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practical value. Small molecules have also been used to promote
the effect of transcription factors by modifying chromatin in the
donor cells. Examples include 5-aza-deoxycytidine which pro-
motes demethylation of DNA (Wernig et al., 2008) and valproic
acid which inhibits incorporation of a histone deacetylase (HDAC)
(Huangfu et al., 2008). Similar beneﬁcial effects were seen when
the powerful transactivator from MyoD, the gene that has a
dominant role in inducing muscle formation, was incorporated
alongside the Oct4 coding sequences (Hirai et al., 2012). Incor-
poration of ascorbic acid in the culture medium had an unex-
pected effect upon the reprogramming process (Esteban et al.,
2010). Further analysis showed that this effect reﬂected the abil-
ity of ascorbic acid to enhance the activity of two H3K36 deme-
thylases (Jhdm1a/1b). This effect resulted from acceleration of cell
cycle progression and suppression of senescence by Jhdm1b,
which also cooperates with OCT4 to activate the microRNA cluster
302/367 an integral component of the pluripotency network
(Wang et al., 2011). Ascorbic acid was also shown to reduce
hypermethylation of the imprinted gene cluster Dlk1-dio3 by
preventing the binding of the DNAmethyltransferase DNMT3A. As
a result of these effects, mouse iPSCs produced from mature B-
cells in the presence of ascorbic acid acquired the ability to form
offspring by tetraploid embryo complementation which was
derived exclusively from iPSCs (Stadtfeld et al., 2012). Taken
together these observations emphasise the importance of the
epigenetic environment in determining the efﬁciency and accu-
racy of cellular reprogramming.
A number of observations point to the importance of cell divi-
sion in the process of reprogramming. A beneﬁcial effect of the
incorporation of c-MYC in the reprogramming recipe was inter-
preted as reﬂecting an effect on the cell cycle. Similar effects were
seen during a detailed analysis of the effects of overexpression of a
different oncogene, LIN28 or of the inhibition of the p53 pathway.
Both of these changes increased the speed of reprogramming in
direct proportion to the increase in cell division (Hanna et al.,
2009). The addition of NANOG to the regime establishes
enhanced reprogramming through a network of other transcrip-
tional factors once factors such as OCT4 have been instituted
(Hanna et al., 2009).
Two other means of enhancing the efﬁciency of reprogramming
have been described. Serum starvation before treatment led to an
increase in the effectiveness of standard reprogramming in both
skin ﬁbroblasts and adipose stem cells (Chen et al., 2012). The
protocol may have synchronised cells in G0/G1 such that when
released they passed through the next mitosis as the transgenes
ﬁrst expressed the reprogramming proteins. Selection of ﬁbroblasts
that expressed the embryonic antigen SSEA-3 before treatment also
led to increased efﬁciency in reprogramming (Byrne et al., 2009).
No iPSCs were obtained from those cells that did not express SSEA-
3. It seems very likely that other means of enhancing reprogram-
ming to a pluripotent state remain to be discovered. For instance, it
has been shown that it is possible to remove C-MYC from the
regime with the addition of a microRNA cluster (Judson et al.,
2009). This may be of relevance when creating lines for clinical
use to reduce the oncogenic risk.
Although signiﬁcant progress has been made in reprogramming
technologies the ideal protocol is still not currently available and
the protocol selected is a balance between each of the paradigms
described. The choice of protocol is dependent on the ﬁnal aims of
the reprogramming. If reprogramming is used to study mecha-
nisms of reprogramming alone then amouse cell can be usedwith a
cheaper and more robust and integrated methodology. However, if
replicating human physiology or clinical cell replacement is
required then a biologically inactive, integration free methodwould be more suitable using human cells preferably not con-
taining any mutagenic transcription factors.
2.5. Donor cell
A further factor to consider is the donor cell type. To date
most reprogramming has been performed through donor ﬁbro-
blasts. These cells are easy to obtain and robust in culture.
However, they are not the most efﬁcient cells to reprogram.
Additionally, the punch biopsy procedure is invasive and not
suitable for use in young children. A number of other cell types
have also been used for reprogramming including keratinocytes
(Aasen et al., 2008), melanocytes (Utikal et al., 2009) and cord
blood (Giorgetti et al., 2009). Recently, a number of groups used
constituents of whole blood including circulating T-cells and
endothelial progenitor cells obtained by venepuncture (Howden
et al., 2011; Geti et al., 2012; Phillips et al., 2012). This offers
the obvious advantage of using samples from routine testing that
can be easily transported. Efﬁciency and ease of reprogramming
varies between donor cell types. This is thought to be due to
variations in endogenous expression of transcription factors (Kim
et al., 2010) (Fig. 1).
2.6. Selection of hiPSCs
Use of hiPSCs is complicated by the derivation of partially
reprogrammed cells alongside fully reprogrammed ones. In these
circumstances it is essential to carry out a rigorous assessment of
cell lines prior to use in order to conﬁrm that reprogramming is
complete. The main tools to characterise hiPSCs are summarised in
Table 3 and Fig. 2.
Morphologically stem cell colonies have a high rate of cell di-
vision. Cells are tightly packed with large nuclei. Cell surface
markers include SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81
(Takahashi et al., 2007). More recently use of live-cell staining
techniques has become possible for markers such as TRA-1-60 to
assist in the isolation of pluripotent colonies. Routine reverse
transcription and polymerase chain reaction (rtPCR) can be used to
conﬁrm expression of factors associated with pluripotency
including NANOG, OCT4, SOX2, REX1 and hTERT (Takahashi et al.,
2007). Pluripotency can be conﬁrmed by a number of methods.
Transplanting hiPSCs into immunodeﬁcient mice to show teratoma
Table 3
Methods commonly used to validate hiPSCs.
Characteristic Expected results
Morphology Flat colonies
High nuclear to cytoplasmic ratio
Small, round shape
Cellular markers Nanog, Sox2, Oct4
Cell surface markers SSEA-3, TRA-1-60, TRA-1-81
rtPCR/ICC NANOG, OCT4, SOX2, REX1 and hTERT
Bisulphite sequence analysis Promoter methylation status of the
endogenous pluripotency genes
Quantitative PCR (silencing of the
exogenous reprogramming factors)
NANOG, OCT4, SOX2, C-MYC, KLF4
Karyotyping Chromosomal stability
Teratoma formation/embryoid body
formation
Standard teratoma formation to test
pluripotency is performed in
immunodeﬁcient mice, injection routes
are sub-renal capsule, subcutaneous or
intramuscular. Differentiation capacity
of hiPSCs to three germ-layers;
endoderm, mesoderm and
neuroectoderm
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2008). A cheaper alternative is to show embryoid body formation
in vitro in order to show functional pluripotency (Itskovitz-Eldor
et al., 2000; Kurosawa, 2007). Using this methodology hiPSCs are
differentiated using standardised protocols to develop cells from
different germ layers. Differentiation can be conﬁrmed by immu-
nostaining and RNA expression (Fig. 2).Fig. 2. Characterisation of pluripotency. In order to reprogram human somatic cells the c
employed to introduce reprogramming transcription factors into cells. These are summarise
which have hESC-like properties. Traditionally a range of techniques has been used to identif
cellular, molecular, functional and quality control streams for validation of pluripotency.More recently, molecular assessments have been made. This
may involvemonitoring gene expression by gene array to assess the
function of either selected gene populations or the entire genome.
As reprogramming depends upon major changes in the epigenome,
direct measurements have been made of the epigenetic status of
the cell during and following treatment. These include assessment
of the promoter regions of key pluripotency genes or genome wide
assessment of DNA methylation, histone methylation and acetyla-
tion. By combining a number of these observations several labo-
ratories have developed schemes for the selection of those lines
that have been reprogrammed accurately (Bock et al., 2011; Chan
et al., 2009). Others have placed great emphasis on correct regu-
lation of imprinted genes (Lujan and Wernig, 2010). Most recently,
a systematic survey of cell surface glycoproteins has been initiated
with the hope that this may deﬁne cell surface patterns that are cell
type speciﬁc (Gundry et al., 2012). Consequently, the landscape of
validation is constantly evolving.
In practice it is likely that most research laboratories will be
satisﬁed with a relatively modest survey of markers and function. It
is greatly hoped that in the near future methods for hiPSC pro-
duction will become sufﬁciently reproducible and accurate that
extensive assessment will no longer be required unless the cells are
to be used for cell therapy.
3. Retinal differentiation
During human embryogenesis the inner cell mass of the blas-
tocyst forms the epiblast. The epiblast divides into the embryonicells are ﬁrst isolated and cultured in vitro for expansion. Various methods have been
d in Table 2. Only a small proportion of the donor cells will form pluripotent colonies
y pluripotent cells. The common techniques are illustrated here and can be divided into
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the neuroectoderm occurs from the ectodermal germ layer. The
retina arises throughmid-ventral and rostral patterning and results
in the formation of the optic grooves from the rostral diencephalon,
part of the primitive forebrain. Later, the optic grooves protrude to
form optic vesicles. At a cellular level, hESCs undergo stepwise
differentiation through neural and retinal progenitor stages before
differentiating to either RPE or neuroretinal cell types (Fig. 3).
In vitro retinal differentiation protocols for hiPSCs have been
developed on the groundwork of hESC studies. HESCs have been
shown to recapitulate the differentiation of retinal cells in vivo
(Klimanskaya et al., 2004; Lamba et al., 2006; Meyer et al., 2009;
Osakada et al., 2008). In vitro retinal differentiation protocols for
hiPSCs are broadly divided into twomain categories. Firstly, default
differentiation, in which cells are cultured in the absence of
extrinsic growth factors. Secondly, directed differentiation pro-
tocols, in which differentiation requires the addition of extrinsic
transcription factors, proteins and small molecules. Currently, no
differentiation protocol is absolutely efﬁcient in its production of
retinal cells. Therefore the choice of differentiation protocol de-
pends on the resources available, the aims of the research and the
ﬁnal purity of cell population required.3.1. Default differentiation
In an incompletely understood mechanism, human pluripotent
cells differentiate to neural lineages, including those of the retina,
in the absence of exogenous factors (Munoz-Sanjuan and Brivanlou,
2002). This is often known as the default model of pluripotent cell
differentiation. There is increasing evidence from mammalian ES
cell studies that this results from a cell intrinsic mechanism
(Kamiya et al., 2011; Smukler et al., 2006).
Fibroblast growth factor, activin and Nodal have been shown to
be key regulators of pluripotency in human pluripotent cells
(Vallier et al., 2005). Removing basic FGF from pluripotent cell
maintenance media initiates differentiation (Reubinoff et al., 2001).
Neuroectodermal induction requires suppression of other differ-
entiation pathways including those to mesodermal and endo-
dermal cell fates. In default differentiation this is thought to resultFig. 3. Retinal differentiation of pluripotent stem cells. Pluripotent cells differentiate throu
Differentiation to RPE requires the continued expression of MITF without up-regulation of
CHX10 with suppression of MITF. Expression of these key regulators is modiﬁed by FGF, TGfrom the suppression of bone morphogenetic protein (Tropepe
et al., 2001). Differentiating cells appear to follow embryologic
differentiation pathways in which the pluripotent cells attain a
retinal progenitor stage before expressing more mature retinal cell
markers including those for RPE and neuroretina (Vugler et al.,
2008). RPE cells can be identiﬁed by melanin pigmentation
within four weeks of differentiation in default culture conditions
(Carr et al., 2009). Isolation, culture and expansion of patches of
pigmented polygonal cells can be used to derive conﬂuent mono-
layers of RPE. This is perhaps the simplest of protocols for differ-
entiation of RPE and requires little specialised media or
intervention. This also means that large volumes of hiPSCs can be
grown. However, limitations include the relative inefﬁciency of
differentiation resulting in a mixture of cell types potentially
wasting expensive media. Additionally, some lines may not have an
intrinsic capacity for retinal differentiation which may be depen-
dent on endogenous expression of retinal differentiation genes
(Mellough et al., 2012). This is supported by analysis of the tran-
scriptome from RPE cells following differentiation shows marked
variation in RNA expression. This suggests that inherent differences
between cell lines could lead to differences in retinal differentiation
(Liao et al., 2010; Strunnikova et al., 2010).3.2. Directed differentiation
Directed differentiation is a method that guides cell differenti-
ation with the addition of exogenous factors. Patterning occurs
rapidly during embryogenesis. Germ layer cell fate is determined as
early as the end of the ﬁrst week. Table 4 summarises the tran-
scription factors, proteins and small molecules used in directed
differentiation to retina.
It is has already been demonstrated that pluripotent cells pass
through an anterior neuroectoderm like stage when recapitulating
retinal differentiation in vitro (Meyer et al., 2009) (Fig. 3). A number
of published protocols have attempted to increase the efﬁciency of
differentiation to neuroectoderm from pluripotent cells. Chambers
et al. showed that neuralisation increased to over 90% with inhi-
bition of the SMAD signalling pathway using the protein NOGGIN
and the small molecule SB431542. This contrasts with less than 10%gh neural and retinal progenitor stages. MITF is a marker for retinal progenitor cells.
CHX10. Alternatively differentiation to neuroretina requires the enhanced expression
F-b and WNT signalling (Meyer et al., 2009; Nguyen and Arnheiter, 2000).
Table 4
Summary of commonly used transcription factors, proteins and small molecules in
retinal directed differentiation protocols.
Factor Normal function
Noggin Noggin is a protein which prevents binding of TGF-b
ligands to their receptors. Noggin plays a key role in
neural induction by inhibiting bone morphogenetic
protein.
SB431542 Small molecule used to selectively inhibit the TGF-
b1 receptor. Initially used to suppress
differentiation of osteosarcoma cells.
Lefty Important in left-right patterning. Lefty is an
antagonist of Nodal signalling.
DKK-1 (Dickopf-related
protein 1)
A protein which is an inhibitor of the WNT
signalling pathway.
Sonic Hedgehog A protein important in ventral/rostral patterning of
the brain and limbs.
Nicotinamide An amide of vitamin B3/niacin. Although the
mechanism of action is incompletely understood
there is increasing evidence to show that
nicotinamide promotes neuralisation and reduces
apoptosis.
Activin A A member of the TGF-beta superfamily. Activin A
interacts with the Nodal and WNT systems and has
a wide range of biological activities, including
mesoderm induction, neural cell differentiation,
bone remodelling, haematopoiesis and roles in
reproductive physiology.
IWR1-Endo Small molecule inhibitor of WNT signalling.
CHIR99021 Selective inhibitor of glycogen synthase kinase 3.
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(Chambers et al., 2009). Similar results have been found by a
number of other groups who have showed dual SMAD inhibition
was greater than inhibition of a single SMAD pathway (Lee et al.,
2007; Smith et al., 2008) (Fig. 4). Osakada et al. also investigated
the use of the small molecules in SMAD inhibition. It was suggested
these non-antigenic small molecules would be advantageous in the
derivation of cells used for cell replacement therapies. Casein ki-
nase 1 when used in combination with SB431542 showed a similar
efﬁciency to LEFTY and DKK-1 (Osakada et al., 2008). Taken
together these studies demonstrate the importance of modifying
Nodal, WNT, BMP and TGF-b in early neuroectodermal patterning.
The composition of mediamay also play a part in differentiation.
B27 (Lu et al., 2009) or N2 (Meyer et al., 2011) supplementation has
recently been shown to be important in accelerating neural and
retinal differentiation (Mellough et al., 2012). Traditionally, in vitro
differentiation has been performed at atmospheric oxygen con-
centration (20%). This is markedly different from in vivo oxygen
levels in tissues which are likely to be in the range 2e5% (ErecinskaFig. 4. Summary of the effects of dual SMAD inhibition with NOGGIN and SB431542. Du
consequently drive differentiation. Neuralisation is promoted by the suppression of altern
ectoderm.
Adapted from Chambers et al., 2009and Silver, 2001). Hypoxia is thought to activate the phosphatidy-
linositol pathway and lead to downstream up-regulation of S6, HIF,
cyclin and BCL which all play a part in cell growth and proliferation.
A 3% oxygen concentration increases the percentage of viable cells
at the neuroectodermal stage (Stacpoole et al., 2011).
3.2.1. Directed differentiation to RPE
After the primitive anterior neuroectodermal stage of differen-
tiation, cells that ultimately have a retinal cell phenotype undergo a
critical switching. Cells which differentiate to RPE increase MITF
expressionwhilst those that differentiate to neuroretina upregulate
CHX10 expression and suppress MITF (Fig. 3).
Addition of activin-A has been found to increase MITF expres-
sion 8.3 fold (2.5) and also convert a subset of optic vesicle like
structures to an RPE fate (Meyer et al., 2011 Stem Cells) (Fig. 3).
Idelson et al. (2009) found that the addition of nicotinamide to
activin-A resulted in a further increase of RPE differentiation from
hESCs. The exact mechanism of action of nicotinamide was not
investigated. Nicotinamide has subsequently been used at both
initial and late stages in protocols to differentiate hiPSCs success-
fully (Kokkinaki et al., 2011; Ukrohne et al., 2012). It is thought to
have an anti-apoptotic promoting neuronal cell viability
(Cimadamore et al., 2009). Recently, a combination of factors which
had been used in previous protocols demonstrated a rapid differ-
entiation of hESCs and hiPSCs to RPE. Buchholz et al. (2013) used a
combination of DKK-1, Noggin, nicotinamide and insulin-like
growth factor, with the later addition of FGF and activin-A to pro-
duce expandable pigmented RPE population which was identiﬁed
as early as day 14.
RPE forms easily identiﬁable pigmented, polygonal colonies. The
differentiated RPE can be mechanically dissociated before replating
for expansion (Lu et al., 2009). Expansion of cells has been
described using various concentrations of foetal calf serum (2e10%)
(Sonoda et al., 2009). A serum free method has been described
using media containing basic FGF and EGF supplemented with
heparin (Gamm et al., 2008; Lu et al., 2009). RPE appears to un-
dergo rapid senescence with passaging. By passage 3 hiPSC-RPE
were found to have telomeres which were 60% shorter than the
original hiPSCs. Additionally, cells were noted to have marked DNA
damage at later passages (Kokkinaki et al., 2011). As well as being
propagatable, hiPSC-RPE can also be banked for later use (Lu et al.,
2009; Nakano et al., 2012).
A deﬁnition of hiPSC-RPE is relevant for both modelling and
transplantation studies in order to ensure that there is similarity to
the in vivo cell phenotype and also to allow comparison between
readouts from derived cells lines. Although a standard deﬁnition of
RPE has yet to be agreed, a range of characteristics can now beal SMAD inhibition is proposed to interfere with TGF-b and Nanog interactions and
ative potential cell fates. This results in the formation of a primitive anterior neuro-
Table 6
Markers of different stages of retinal cell differentiation.
Stage Markers
Pluripotent cell OCT4, SOX2, TRA-1-60, NANOG
Epiblast FGF5þ
Primitive anterior neuronal PAX6, OTX2
Anterior neuroepithelial PAX6, OTX2, SOX1
Eye ﬁeld Rx, SIX3, SIX6, LHX2
Optic vesicle PAX6, MITF, CHX10
RPE progenitor PAX6, MITF
Neuroretinal progenitor PAX6, CHX10
Photoreceptor RECOVERIN, OPSIN, CRX
Mature RPE BEST1, ZO-1, CRALBP, RPE65,
PEDF, MITF, SILV, MerTK.
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include morphological, molecular and functional features (Table 5).
Certain markers continue to be expressed in hESC/hiPSC-RPE
despite prolonged culture, including PAX6. RPE speciﬁc markers
include those for phagocytosis such as MERTK and the basal
marker, BEST1. Apical membrane associated markers include Naþ/
KþATPase and Ezrin. Pigmentation markers include tyrosinase and
secreted growth factors such as pigment epithelium derived factor
(PEDF). Visual cycle markers include RPE65, LRAT and CRALBP
(Bharti et al., 2011).
3.2.2. Directed differentiation to neuroretina
Several methods of achieving highly enriched populations of
hiPSC-derived neuroretinal progenitor progenitor cells (NRPCs)
have been described that utilise neuroretinal fate-biasing culture
media (Hirami et al., 2009; Jin et al., 2011; Lamba et al., 2010;
Mellough et al., 2012; Osakada et al., 2009). Both hESC- and
hiPSC-derived neuroretinal progenitor cells (NRPCs) differentiate in
a similar manner, mimicking the order and time course of normal
retinogenesis (Meyer et al., 2011; Meyer et al., 2009; Phillips et al.,
2012) (Table 6). Lamba et al. (2006) showed that hESCs could be
directed to a neuroretinal cell fate with the addition of NOGGIN,
DKK-1 and IGF-1. Cells were then maintained in basic FGF for 3
weeks. The protocol led to a 75e165 fold increase in the expression
of eye ﬁeld transcription factors RX, PAX6, SIX3 and LHX2 when
compared with cells grown in media without additional factors.
However, the protocol failed to produce mature photoreceptors
with high efﬁciency with less than 0.01% of cells expressing S-OPSIN
and RHODOPSIN (Lamba et al., 2006).
Guided by murine and primate studies, Osakada et al. used
extended culture with the addition of retinoic acid and taurine to
the culture medium of hESCs. Crx positive photoreceptor pre-
cursors increased from 11.3% of total cells on day 120 to 19.6% of
total cells by day 170. This was mirrored by an increase in cells with
a mature photoreceptor phenotype. Rhodopsin positive rod pho-
toreceptors increased from 5.1% on day 150 to 8.5% of total cells on
day 200. The protocol also generated cones with red/green opsin
making 8.9 of total cells and blue opsin 9.4% of total cells (Osakada
et al., 2008). More recently, Mellough et al. described a more
complex protocol which investigated combinations of factors used
by previous published protocols. Using ﬂow cytometry, markers for
mature photoreceptors peaked at day 45. However, this declined
rapidly by day 60 with almost complete loss of rhodopsinTable 5
Summary of characteristics of RPE veriﬁcation.
Feature Markers
Morphology (light microscopy) Pigmentation, polygonal, monolayer
Morphology (transmission
electron microscopy)
Apical microvilli, intracellular pigment
granules, tight-junctional complexes
across and basement membrane
formation
Loss of pluripotency markers OCT3/4, SOX2, NANOG
Non-speciﬁc RPE markers MITF, SILV, PAX6, OTX2, Claudin-10
RPE speciﬁc markers Phagocytosis: MERTK, FAK
Pigmentation: Tyrosinase
Growth factors: Pigment epithelium
derived growth factor
Visual cycle: RPE65, RLBP1, CRALBP
Polarity Resting membrane potential
Apical staining: Ezrin, Naþ/KþATPase
Basal staining: BEST1
Phagocytosis Photoreceptor outer segment
phagocytosis assay
Tight junction formation ZO-1 staining, transepithelial resistance
>150 Ohms per cm2(Mellough et al., 2012). The ﬁndings are different from other groups
who found increases in photoreceptor markers with time (Osakada
et al., 2008; Phillips et al., 2012), however, they suggest that
photoreceptor differentiation can be accelerated. HESC studies have
since been conﬁrmed using hiPSC lines. Lamba et al. (2010)
demonstrated similar results with hiPSC differentiation. The per-
centage of cells expressing markers of mature photoreceptors was
still less than 1% of total cells after two months of culture. Similarly
Osakada et al. found similar efﬁciency with disease and control
hiPSCs (Jin et al., 2011; Osakada et al., 2009).
While it is clear that pluripotent stem cells produce neuroretinal
progeny, identifying these cells in living cultures poses a challenge.
Unlike RPE, plated clusters of differentiating neuroretinal cells are
not readily discernible from non-retinal neural cell populations by
direct visual or light microscopic inspection. Thus, a means to
isolate NRPCs and/or their progeny fromunwanted or unknown cell
types in culture is a necessary step prior to transplantation in
humans. Mechanically manipulated hESC and hiPSC cultures can be
manipulated into generating populations of free-ﬂoating neural
aggregates containing NRPCs, termed “OV structures” (Meyer et al.,
2011). Since they share a number of properties with embryonic
optic vesicles, they can be readily isolated based on their distinct
appearance in culture and grown in bulk culture using a simple
media formulation. Initially, these hiPSC-OVs consist of a nearly
uniform population of proliferating CHX10þ NRPCs, but over time
they produce cells expressing photoreceptor and other neuroretinal
cell markers (Meyer et al., 2011; Phillips et al., 2012).
The future of hiPSC derived neuroretinal differentiation perhaps
lies in the generation of a three-dimensional whole neuroretina
which recapitulates retinal development in vitro. This was ﬁrst
demonstrated using murine ESCs (Eiraku et al., 2011) as has since
been conﬁrmed using hESCs by Nakano et al. (2012). Using this
protocol hESCs were suspended in media containing WNT antag-
onist IWR1-endo, hedgehog smoothened agonist anti-apoptotic
agent Y-27632 and 1% Matrigel. Addition of 10% FBS was found to
markedly increase retinal progenitor formation with greater than
70% of cells found to be Rx positive by ﬂow cytometric analysis.
WNT agonist CHIR99021 was added temporarily following which a
double walled optic cup structure self-forms from the invagination
of the distal vesicle. Retinal photoreceptor maturation appeared to
mirror foetal development in timing. However, the protocol still
requires optimisation in order to produce photoreceptors with
outer segments (Nakano et al., 2012). In addition, hiPSC-derived
NRPCs also have the capacity to self-assemble into laminated
retina-like structures (Phillips et al., 2012). When hiPSC-derived
OVs were isolated and followed over time, a subset gave rise to
multilayered retina-like structures (w16%). While the percentage
of OVs that maintained laminated retinal architecture was modest,
the use of aminimal culture systemdemonstrated the innate ability
of hiPSCs for self-assembly. Long term neuroretinal culture was
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physiological oxygen levels have recently been shown to increase
differentiation efﬁciency to both retinal progenitor and neuroretina
(Bae et al., 2012; Garita-Hernandez et al., 2013). The difference may
demonstrate that low oxygen tension plays a role in differentiation
replicating in vivo conditions but that the maintenance of multi-
layered organ structures in vitro requires a higher oxygen tension
without a blood supply.
Several protocols have been reported for the generation of
photoreceptors and other neuroretinal cell types from hiPSCs for
cell replacement therapy. However, it is critical that these donor
cells are functional for transplantation to be successful and for
modelling of certain retinal diseases. Previous studies have sug-
gested that neuroretinal cells derived from hiPSCs form chemical
and electrical synapses in culture (Phillips et al., 2012), that these
cells have an electrophysiological proﬁle consistent with photore-
ceptors (Jin et al., 2011; Meyer et al., 2011), and express key com-
ponents of the phototransduction cascade (Meyer et al., 2011). A
recent study by Nasonkin et al. highlighted the critical function of
RPE in outer segment formation in vivo. While Dnmt1 knockout in
photoreceptors had no effect on photoreceptor outer segment
genesis, RPE-speciﬁc Dnmt1 knockout led to disrupted RPE apico-
basal polarity and pronounced defects in outer segment produc-
tion (Nasonkin et al., 2013). Indeed, a study byMcUsic et al. showed
the importance of RPE-photoreceptor co-culture by culturing
neonatal mouse photoreceptors in a microchannel scaffold, sand-
wiched on top of an RPE explant culture (McUsic et al., 2012). Using
this culture method, photoreceptors formed disorganised outer
segment material. Further studies are required to delineate
methods for forming true photoreceptor outer segments in vitro.
Outer segment formation will be critical for hiPSC disease model-
ling studies, as the majority of photoreceptor-based retinal disor-
ders arise from mutations in proteins localised to the outer
segment. In vitro outer segment formation is less critical for
transplantation therapy, as transplanted photoreceptors may uti-
lize the host environment and RPE to generate outer segments
post-transplant.
3.3. Direct lineage conversion
The creation of hiPSCs demonstrated that deﬁned factors can
transform a terminally differentiated somatic cell to a pluripotent
cell and stabilise a new epigenetic framework. A disadvantage of
hiPSC based reprogramming is that somatic cells require trans-
formation to a developmental ‘ground state’ before rediffer-
entiation to the cell type of interest. Building on this work, it was
proposed that terminally differentiated cells could be directly
reprogrammed to other terminally differentiated cells without the
need for a pluripotent intermediary. This may provide several ad-
vantages for cell therapy as it allows a means of deriving retinal
cells without the associated difﬁculties in differentiation and
maintenance of hiPSCs. This may be of especial beneﬁt in protocols
which currently have lengthy differentiation protocols such as
those used in hiPSC-derived neuroretina. This process has been
variously called direct lineage conversion, direct conversion or
direct reprogramming. Work by Davis et al. (1987) demonstrated
the introduction of a single transcription factor MyoD was able to
convert mouse ﬁbroblasts to myocytes. This suggested that there
weremaster transcription factors that could regulatemany genes to
facilitate conversion in a transcriptional network. There are now
several papers demonstrating that it is possible to alter cells from
one somatic phenotype to another by introducing relevant tran-
scription factors (Ieda et al., 2010; Szabo et al., 2010; Vierbuchen
et al., 2010). Recently, an attempt was made to derive retinal cells
using direct conversion from human ﬁbroblasts. Zhang et al.developed a Best1: GFP reporter system to investigate the role of
eight candidate transcription factors in direct conversion of ﬁbro-
blasts to RPE. It was found that c-Myc, Mitf, Otx2, Rax, and Crx were
essential for successful conversion to RPE-like cells. Daughter cells
showed RPE-like expression proﬁles and stained for several RPE
markers, but no functional analysis was provided (Zhang et al.,
2013). Detailed veriﬁcation will be important to show whether
this technique is viable for the production of clinically relevant
retinal cells.
Although direct lineage conversion techniques are more efﬁ-
cient than reprogramming to pluripotency, at present a maximum
of one daughter cell forms from each donor cell. Therefore large
quantities of donor cells would be needed to generate required
cellular material. This issue could be resolved by reprogramming to
a progenitor stage with subsequent more limited expansion when
compared with hiPSCs. Recently, advancements have been made to
realise this goal that could have implications for ophthalmic
research. Using nine transcription factors murine mesodermal cells
were converted to induced neural precursors. The precursor was
both expandable and could be differentiated to the three neural
lineages (Sheng et al., 2012). Other groups have now published
protocols using as little as two factors to produce an expandable
neuronal precursor with conversion varying from three days to one
month with murine cells (Han et al., 2012; Lujan et al., 2012; Thier
et al., 2012). Presently, no group has been able to demonstrate
direct conversion to a retinal precursor.
Another barrier to the development of direct lineage reprog-
ramming protocols is the requirement for complex transcriptome
and bioinformatic analysis in order to identify potential transcrip-
tional targets. This is likely to become easier as bioinformatics be-
comes more efﬁcient. However, much remains to be learnt about
the most effective way to use this evolving methodology in retinal
research.
4. Clinical applications of hiPSC derived retinal cells
4.1. Disease modelling
As robust protocols have been established for the efﬁcient,
reliable generation of hiPSC-derived retinal cells, there has been an
increased focus on developing clinical applications for retinal dis-
ease treatment (Fig. 5). The major attraction of hiPSC-based disease
modelling is the potential to differentiate phenotype-relevant cell
types that would enable the investigation of disease mechanisms in
the context of specialised cellular physiology. In the routine
context, functional human retinal cells are difﬁcult to obtain and
maintain. Consequently, this has led to the adoption of immortal-
ised cell lines. However, these cellular systems are removed from
the physiology of the post-mitotic, specialised cell types that are
affected in human disorders, confounding inferences that can be
gained about disease processes. HiPSC derived retinal cells are able
to recapitulate key physiological and functional in vivo character-
istics. This highlights the utility of hiPSC derived retinal cells in
retinal disease modelling.
Recently, several papers have been published describing disease
modelling using hiPSC-retinal cells. For example, a clinically rele-
vant disease phenotype for Best vitelliform macular dystrophy
(BVMD) was observed using hiPSCs from affected patients when
compared to those obtained from unaffected siblings. BVMD is
caused by a defect in the RPE gene BEST1, which results in the
subretinal accumulation of photoreceptor waste products (lip-
ofuscin) and ﬂuid, leading to secondary photoreceptor death and
central vision loss. Using physiological stressors, BVMD hiPSC-RPE
showed evidence of a similar functional defect on a cellular level
in vitro. Further analysis of BVMD and paired control hiPSC-RPE
Figure 5. Diagram summarising potential clinical applications of retinal cells derived from hiPSCs.
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system suggested a role for intracellular calcium regulation and
oxidative stress in the mechanism of disease. Similarly disease
relevant biomarkers were discovered in a neuroretinal model for
retinitis pigmentosa using hiPSC-rod photoreceptors from cases
and controls. The model showed increased expression of markers
for oxidative and endoplasmic reticulum stress (Jin et al., 2011).
Both of these studies highlight the potential of RPE and neuro-
retinal cells derived fromhiPSCs to help identify pathophysiological
pathways for targeted development of therapies.
The importance of modelling using human retinal cells rather
than animal models or more easily accessible tissue was recently
demonstrated by Tucker et al. who derived hiPSCs from a patient
with sporadic RP. HiPSC retinal precursors were used to verify the
pathogenicity of a homozygous Alu insertion into the causal gene
uncovered by exome sequencing (Tucker et al., 2011). In this elegant
study, the authors found that the insertion of the Alu sequence into
exon 9 of the patient’s male germ cell-associated kinase (MAK) gene
prevented the expression of a splice variant ofMAK that is normally
expressed only in retinal precursors. In this case, hiPSCs offered an
efﬁcient means of identifying the disease mechanism by enabling
the ex vivo study of patient-speciﬁc retinal cells.
Notwithstanding the value of studying isolated single cell
types, it is clear that accurate modelling of disease processes re-
quires development of more complex 3D systems that also
incorporate other relevant cell types. One such platform is the self
forming eye cup which was initially demonstrated using mouse
embryonic stem (ES) cells (Eiraku et al., 2011) and later using
human ES cells (Nakano et al., 2012) and hiPSCs (Phillips et al.,
2012). The mouse and human ES cultures were produced in dif-
ferentiation media supplemented with matrigel in order to pro-
vide extra cellular matrix. The resultant optic cup was
multilayered and consisted of relevant retinal cell types including
photoreceptors, ganglion cells and interneuron precursors. This
method has the potential for allowing puriﬁcation and propaga-
tion of speciﬁc retinal cells for use in isolation. More importantly,
a three dimensional in vitro structure replicates the correspondingin vivo structure remarkably well, enabling the study of non-cell
autonomous diseases that result from complex interactions of
different retinal cell types.
4.2. Drug screening
Ultimately, hiPSC-based in vitro disease models could be used to
perform compound screening, predictive toxicology and to eval-
uate new therapeutics. All of these screens would require assays
that can be adapted for high throughput platforms. Such assays will
need to be multiplexed to simultaneously assess the proliferation,
morphology, differentiation, viability and function of specialised
cell types that would enable the monitoring of disease-relevant
phenotypes. In 2009, the ﬁrst proof-of-principle hiPSC study was
published that combined a demonstration of in vitro disease phe-
notypes and screening for candidate drugs using familial dysauto-
nomia (FD) hiPSCs (Lee et al., 2009).
To date, there have been a limited number of publications
looking at the effects of drugs on hiPSC-derived retinal cells. Meyer
et al. (2011) reported the restoration of OAT enzyme activity in
gyrate atrophy hiPSC-RPE following vitamin B6 treatment.
Although B6 supplementation is a known treatment for gyrate at-
rophy the donor patient had been initially deemed unresponsive to
vitamin B6 following surrogate clinical tests. The identiﬁcation of
B6 response in hiPSC-RPE suggested that systemic treatment in the
patient would yield a beneﬁcial clinical response. Therefore, this
study underscored the potential importance of using custom
hiPSCs to test the actual cell types targeted by a disease in order to
more accurately assess drug efﬁcacy. Similar studies in cardiology
have led to drug testing that carries implications for dosing in
humans and similar studies in the retina may be equally beneﬁcial
(Moretti et al., 2010).
HiPSC lines were created from patients with mutations in genes
associated with RP, including RP1, PRPH2, RHO, and RP9 (Jin et al.,
2011). In this study, the authors noted death of RHODOPSIN-
positive cells in all disease lines between days 120 and 150 of cul-
ture. However, treatment with a-tocopherol led to a statistically
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carrying the RP9 mutation. Therefore, this study provided proof of
principle that hiPSC technology is useful in screening for drug re-
sponses across numerous related, yet genetically distinct retinal
diseases. This application is particularly important for genetically
and phenotypically heterogeneous disorders like RP, and could ul-
timately help to narrow the disease targets for experimental drugs
and hence inform clinical trial design. HiPSC technology offers an
unlimited source of material for automated, high throughput drug
screening systems to screen libraries of drug compounds. Ulti-
mately, this will enhance drug discovery whilst concurrent toxi-
cology studies will shorten the steps to phase 1clinical trial.
4.3. Limitations of the hiPSC platform: planning for disease
modelling and toxicology studies
The ﬁrst wave of ‘proof-of-principle’ studies has clearly
demonstrated the utility of hiPSC-based disease models. However,
they have also underscored a number of issues, both inherent to the
reprogramming technologies and related to the downstream ap-
plications, which are yet to be resolved. Several molecular differ-
ences between hESCs and hiPSCs have now been established.Fig. 6. Diagram summarising the similarities and differences between hESC and hiPSC cultur
inner cell mass of the developing blastocyst. Cells form rapidly dividing, ﬂat, densely packed
the introduction of speciﬁc reprogramming factors into human somatic cells using various
require regular passaging. With prolonged culture and high passage number the risk for chr
harbouring an abnormal karyotype, copy number variation and point mutation following th
tissue. Epigenetically, cells can exhibit DNA methylation defects and aberrant histone modiAccumulating evidence suggests that most of these differences can
result from differences in genetic background, passage number,
viral integration, derivation conditions, clonal variations and source
of primary cells used for reprogramming.
In this section we highlight key issues that need to be consid-
ered prior to planning of human pluripotent stem cell based
experiments.
Pitfalls of hiPSC-based disease modelling include:
I. Genetic and epigenetic differences due to reprogramming
and culture conditions (Fig. 6)es, toge
colonies
method
omosom
e somat
ﬁcationsa. Copy number variations and mutations arising from
reprogramming and extended periods in culture
b. Epigenetic differences: incomplete demethylation and
remethylation in hiPSCs, aberrant X-chromosome inacti-
vation or imprinting, repeat instabilityII. Efﬁcient and scalable derivation of enriched, phenotype-
relevant cell types
III. Development of protocols that mirror in vivo cellular
complexity
a. Generation of functional, adult-like target cells as opposed
to more immature cell typesther with the pitfalls induced by long term culture. HESCs are isolated from the
containing cells with a high nuclear to cytoplasmic ratio. HiPSCs are created by
s including viral vectors. HiPSCs share properties with hESCs. Both cell types
al aberrations and genetic mutation increase. HiPSCs have an additional risk of
ic cell reprogramming. Furthermore, hiPSCs can retain a memory of the donor
. They can also have variable X chromosome inactivation.
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processes into the experimental setupIV. Identiﬁcation of disease-relevant and informative pheno-
types that are technically robust, reproducible and amenable
to high-throughput and high-content approaches4.3.1. Epigenetics
Resetting of somatic cellular identity to a pluripotent state
requires genome-wide epigenetic alterations that can be imper-
fect due to the limitations inherent in reprogramming method-
ologies. A number of studies have shown that hiPSCs can partially
retain the epigenetic memory of the primary cells from which
they originate, ultimately affecting the functional potential of
these cells (Bar-Nur et al., 2011; Kim et al., 2010). In a comparative
study of transcription-factor-based reprogramming of murine
blood cells and ﬁbroblasts it was demonstrated that both hiPSCs
harboured differentially methylated DNA regions (DMRs) that
correlated with their respective cell of origin (Kim et al., 2010), for
example RPE derived hiPSCs showed a greater propensity to
differentiate to RPE than hiPSCs derived from other lineages.
Blood-hiPSCs also displayed a higher efﬁciency for haematopoetic
differentiation potential compared to ﬁbroblast-hiPSCs in
directed-differentiation experiments suggesting that incomplete
erasure of the epigenetic memory of the donor cell can limit the
resulting pluripotent cells’ propensity for differentiation (Hu et al.,
2010). Epigenetic memory can be investigated using methylation
studies.
A number of studies have already demonstrated that X-reac-
tivation does not readily occur during derivation of human hiPSCs
(Pomp et al., 2011; Tchieu et al., 2010). Moreover, the inactive X-
chromosome in hiPSCs can also lose epigenetic silencing during
extended culture, resulting in erosion of dosage-compensation
(Mekhoubad et al., 2012). X-chromosome silencing can be
checked by assessing XIST expression and histone H3-K27 trime-
thylated foci. Preferably valid cell lines can be taken once X chro-
mosome silencing has been conﬁrmed.
Failure of transcriptional activation of epigenetically silenced
regions including the inactive X-chromosome upon reprogram-
ming can impact on the utility of hiPSCs in modelling X-linked
diseases. In Fragile X for example, the disease results from the
epigenetic silencing of the Fragile X Mental Retardation gene
(FMR1) during development due to a triplet-expansion in its un-
translated region. In one study, hiPSCs were successfully derived
from somatic cells of Fragile X patients but the resulting hiPSCs
failed to activate the transcription of FMR1 (Urbach et al., 2010).
Therefore diseasemechanisms and comprehensive controls need to
be kept in mind due to potential epigenetic differences in hiPSCs
which may be relevant for X-linked ophthalmic diseases such as X-
linked retinitis pigmentosa.
4.3.2. Genetics and chromosomal anomalies
Another source of variation in hiPSC-based disease models are
the genetic changes acquired during reprogramming and pro-
longed culture. Stem cell populations propagated in vitro accu-
mulate chromosomal aberrations that include copy number
variations, deletions in tumour suppressor genes and ampliﬁca-
tions associated with oncogenes (Ben-David et al., 2011; Laurent
et al., 2011). Long-term genetic stability of hiPSCs is also a
particular concern in disorders with underlying repeat expansions
such as Huntington’s disease, Friedreich’s ataxia (FRDA) and
Fragile X syndrome (Mattis et al., 2012; Ku et al., 2010; Sheridan
et al., 2011). In studying these models checkpoints against
repeat instability should be incorporated early into the experi-
mental design, paying particular attention to the speciﬁcmechanisms of repeat instability, as well as minimizing the time
in culture. Checkpoints include genotyping regularly and
comparing with baseline, good tissue culture and potentially us-
ing hypoxic conditions for maintenance.
The ﬁrst generation of hiPSCs was created by the expression of
reprogramming factors via integrative viral systems that inevitably
resulted in the genomic insertion of the transgenes. These ap-
proaches not only carry the risk of insertional mutagenesis but also
include the risk of incomplete proviral silencing that can increase
clonal variation. In fact, hiPSC clones generated at a later stage
following removal of transgenes harbour fewer genomic differ-
ences, lending support to the idea that integration of reprogram-
ming factors can be a source of signiﬁcant variation (Soldner et al.,
2009). As discussed above, in order to remove this risk, newer non-
integrative systems should be used for hiPSC generation.
4.3.3. Scale versus purity: limitations of directed differentiation
Although hiPSCs can theoretically give rise to any somatic cell
type, high purity and sufﬁcient scale of production can only be
achieved currently for a limited number of specialised cell types.
Culture heterogeneity is particularly pronounced in neural lineages,
such as the neuroretina where distinct neuronal subtypes originate
from a common progenitor through a series of symmetric and
asymmetric cell divisions that progressively lead to lineage re-
striction (Gotz and Huttner, 2005). Therefore, reliable and consis-
tent derivation of disease-relevant cell types from hiPSCs will
require a combination of strategies that include the ﬁne-tuning of
developmental morphogens to mimic signalling in early embryonic
development, cell type sorting and enrichment to achieve high
purity and yield as described above. Many of these points have
already been discussed above in the RPE and photoreceptor dif-
ferentiation sections.
4.3.4. Extrapolating from in vitro disease-correlates to in vivo
diseases
Two further challenges remain in disease modelling using
patient-derived hiPSCs. Firstly, the generation of disease-relevant
cell types that reﬂect the functional maturity observed in vivo
and, secondly, the identiﬁcation of robust molecular and functional
differences between diseased cell types compared to healthy con-
trols. It is critical that the disease in question has an appropriate
phenotype that can be manifested and assayed in a dish.
In vitro differentiation protocols in different cell lineages have
led to the differentiation of more immature cell types. For instance,
cardiomyocytes derived from hESCs and iPSCs were found to be
phenotypically immature, with electrophysiological properties
similar to that of foetal cardiomyocytes (Kuzmenkin et al., 2009;
Peng et al., 2010). Looking at hiPSC-ERPE, an RNA expression
microarray proﬁle of hESC/hiPSC derived RPE cells, the proﬁle was
found to be similar to foetal RPE. HESC-RPE had 88 transcripts with
a difference compared to foetal RPE and hiPSCs showed 224 sig-
niﬁcant transcript differences. Using hierarchical clustering to
analyse the data, hESC-RPE expression proﬁles clusteredwith foetal
RPE whereas hiPSC-RPE was found in the next hierarchical cluster
(Liao et al., 2010). It was worth noting that the cells in this study
were investigated from as early as 2 months of culture. The time
point of cell selection is important when investigating hiPSC-RPE
phenotype as cells obtain a more mature phenotype with time in
culture (Vaajasaari et al., 2011). HiPSC-RPE perform many of the
functions associated with mature adult RPE including monolayer
formation with tight junctions, production of good transepithelial
resistance, polarized secretion of growth factors, appropriate ﬂuid
ﬂux and ATP induced calcium response (Kokkinaki et al., 2011).
Indeed hiPSC-RPE performed photoreceptor outer segment
phagocytosis better than foetal RPE. Taken together these
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adult RPE disease.
Regarding hiPSC-derived photoreceptor like cells, there con-
tinues to be a need to further optimise differentiation protocols.
Full adult photoreceptor morphology eludes current differentia-
tion protocols. This is highlighted by the lack of production of
outer segments by cultured photoreceptors. Additionally, the
general scarcity of rods in differentiating human pluripotent stem
cell cultures remains a signiﬁcant barrier to retinal disease
modelling. However, this is likely that some of the current difﬁ-
culties can be rectiﬁed by the introduction of co-culture protocols
which more closely resemble in vivo conditions (Nasonkin et al.,
2013). Interestingly, some photoreceptor-expressed RP muta-
tions that target components of the phototransduction cascade
may be conducive to hiPSC modelling. Meyer et al. (2011) showed
that, in addition to expressing key phototransduction genes, hu-
man pluripotent stem cell-derived photoreceptor-like cells
exhibited a change in membrane potential in response to exoge-
nous 8-Br-cGMP, which mimics the switch from a light-adapted to
a dark-adapted state. Thus, opportunities exist to examine the
functional effects of photoreceptor-speciﬁc mutations using
hiPSCs, as long as the limitations of the culture system are kept in
mind. Also, the immaturity of differentiated cell types may not
always be a limiting factor if a developmental disease is investi-
gated (Marchetto et al., 2010), or the underlying disease process is
detectable regardless of model cell immaturity such as a chan-
nelopathy (Itzhaki et al., 2011).
Lack of knowledge of the speciﬁc cell types affected in a dis-
ease or situations where the end stage disease in patients is
markedly different from early stage events can each further
complicate the disease modelling readouts. In vitro disease
modelling can become particularly challenging where more than
one cell type contributes to the manifestation of the disorder. One
such case has been demonstrated for amyotrophic lateral scle-
rosis (ALS) with SOD1 mutations where disease-onset was shown
to be inherent to motor neurones whereas neurodegeneration
was driven non-cell autonomously by astrocytes (Di Giorgio et al.,
2007). Similarly co-culture techniques for retinal diseases such as
Usher 1B syndrome may clarify whether the disease results from
photoreceptor defects alone or from aberrations in the
photoreceptor-RPE complex (Williams and Lopes, 2011). Model-
ling of complex diseases will eventually require taking into
consideration the environment within which the vulnerable,
specialised cells reside and designing experimental setups that
utilize multiple enriched cell types from hiPSCs to model non-cell
autonomous interactions. This can potentially be investigated
with co-culture experiments.
Determining robust in vitro disease-associated phenotypes
will become increasingly important for drug discovery and
screening studies. Culture heterogeneity and dynamics can mask
subtle differences, necessitating the adoption of sensitive
methods such as real-time single-cell longitudinal survival
analysis to demonstrate differences (Bilican et al., 2013). There is
usually a balance between the speed, sensitivity and scaling-up
of assays used to assess cellular phenotypes. It may be neces-
sary to identify surrogate markers of disease-phenotypes, for
example in cases where the main disease-relevant readout is a
biochemical assay that is not readily adaptable to a high-
throughput format. It is therefore imperative to consider at the
early experimental design stage of hiPSC-based in vitro disease
models if and how the physiological phenotypes would manifest
in the cells that are obtained from directed differentiation, how
such differences would be measured and how many controls are
necessary to document in vitro disease-correlates given natural
variations in phenotypes.4.4. Cell transplantation
The central nervous system (CNS), and the retina in particular, is
an appealing target for cell replacement strategies due to poor
ability of these tissues to self-repair. Additionally, despite the
multitude of clinically identiﬁed neurodegenerative disorders there
is currently a dearth of therapeutic options. The eye has several
advantages over other CNS structures as a target for cell replace-
ment strategies. These include surgical accessibility, clearly un-
derstood anatomy and physiology, and amenability to imaging and
functional monitoring. In addition, the eye is a paired structure that
is relatively isolated from the rest of the body, which reduces the
impact of untoward systemic adverse effects of treatment and al-
lows for comparison to the contralateral eye.
4.4.1. Retinal pigment epithelium
At present, all retinal cell types can be differentiated from both
hESCs and hiPSCs (Rowland et al., 2012). However, successful cell
replacement does not hinge on the ability to produce the target cell
alone. The initial hurdle is to produce and isolate sufﬁcient quan-
tities of the desired donor cell type to implant into the eye. RPE
appears a model cell in this regard. Extended monolayers of RPE
can be isolated and transferred to a variety of substrates (Buchholz
et al., 2009; Carr et al., 2009; Meyer et al., 2011; Meyer et al., 2009;
Singh et al., 2013). In addition, RPE transplantation poses fewer
challenges than neuroretinal cell transplantation, as the former cell
type assumes a relatively simple monolayer structure and does not
require synaptic integration. Consequently, RPE replacement using
pluripotent stem cells has progressed relatively rapidly. Some in-
formation regarding pluripotent cell derived RPE transplantation
has come from a multicentre trial run by Advanced Cell Technolo-
gies for the treatment of dry macular degeneration and Stargardt
macular dystrophy (Schwartz et al., 2012). In these studies, a near
pure population of RPE was obtained from hESCs maintained under
good manufacturing practice (GMP) conditions and injected sub-
retinally. Although results from this safety trial were preliminary,
no untoward effects were seen in treated patients. Similarly, hiPSC-
RPE has recently gained clinical trial authority approval to be used
as the basis for patient treatment (Cyranoski, 2013).
HiPSC-derived RPE cell transplantation data are limited to ani-
mal models at present. Li et al. injected dissociated suspensions of
hiPSC-RPE into the subretinal space of the RPE65 mouse model and
showed some integration with the host RPE, as well as a modest
improvement of visual function as measured by electroretinogram
(ERG) (Li et al., 2012). Meanwhile Carr et al. (2009) showed that
injection of dissociated hiPSC-RPE into the subretinal space of Royal
College of Surgeons (RCS) rats, a model of secondary photoreceptor
degeneration caused by a primary RPE defect, resulted in long-term
preservation of visual function documented by optokinetic head-
tracking. Similar results have been achieved in the RCS rat model
using a wide variety of donor cell types, likely as a result of non-
speciﬁc neuroprotective effects (Idelson et al., 2009; Inoue et al.,
2007; McGill et al., 2007; Wang et al., 2008). However, the fact
that some clusters of transplanted hiPSC-RPE displayed intracel-
lular RHO staining suggested an ability to phagocytose photore-
ceptor outer segments in vivo (Carr et al., 2009), a critical function
that is crippled by the Mertk mutation in RCS rats.
In addition to phagocytosing outer segments, hiPSC-RPE
monolayers cultured in vitro exhibit a number of other important
physiological properties, including formation of tight junctions,
polarized secretion of growth factors, and stimulus-induced
mobilization of intracellular calcium (Buchholz et al., 2009;
Kokkinaki et al., 2011; Meyer et al., 2011; Singh et al., 2013). In
contrast, bolus-injected RPE have not demonstrated such proper-
ties to date. Thus, to optimise the effects on host retinal function, it
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sheets on scaffolds. This strategy may also enhance donor RPE
survival, since natural or synthetic, bioengineered scaffolds could
provide a healthier substrate than host Bruch’s membrane, partic-
ularly if the latter is damaged during the disease process (e.g. in
age-related macular degeneration). Recently, Hu et al. described
such a method to transplant hESC-derived RPE, grown on a 4 mm
thick synthetic scaffold, into the subretinal space of RCS rats (Hu
et al., 2012).
4.4.2. Photoreceptor
Although RPE is a popular target for cell replacement strategies,
from a practical standpoint, most degenerative diseases involving
the RPE that warrant stem cell-based therapies will have already
caused extensive photoreceptor loss. Furthermore, the majority of
inherited outer retinal degenerative dystrophies which are collec-
tively referred to as retinitis pigmentosa (RP) and RP-like disorders,
target photoreceptors, leaving the RPE largely unscathed. There-
fore, it would be of great beneﬁt to devise a means of replacing
photoreceptors, with or without RPE, that have been lost due to
disease or injury. As sources of donor neuroretinal cell types, hu-
man pluripotent stem cells have the distinct advantage of being
both renewable and capable of producing true multipotent neu-
roretinal progenitor cells (NRPCs). Early during their maturation
process, NRPCs are competent to yield all native classes of neuro-
retinal cells, including cones and rods, in a sequence that is highly
conserved across vertebrate species.
While several papers have reported the generation of neuro-
retinal cells from hiPSCs, there are only rare reports of trans-
plantation using these cells. In one study, Lamba et al. (2010)
showed the migration of transplanted hiPSC-derived photorecep-
tors into the outer nuclear layer of a wild-type host mouse retina.
Similar ﬁndings were reported using swine hiPSC-derived photo-
receptors transplanted into the photoreceptor depleted swine
retina (Zhou et al., 2011). In addition, transplantation of mouse
hiPSC-derived photoreceptor precursors into the degenerative Rho
/ retina led to the integration of transplanted cells and limited
restoration of a scotopic ERG response (Tucker et al., 2011).
Although information about transplantation of hiPSC-derived
neuroretinal cells is scarce, insights gained from transplantation
studies using other cell sources are invaluable for the advancement
of cell replacement therapy using hiPSCs. Other cell or tissue
sources that have been used for transplantation studies include
foetal retina, foetal retina-derived photoreceptors, hESC-derived
neuroretina, and photoreceptor precursors isolated from early
postnatal retina. These studies have uncovered a number of hurdles
that face cellular transplantation therapies, which include poor
transplanted cell survival, migration and integration into the host
retina. Previous studies transplanting mouse (West et al., 2012) or
hESC-derived neuroretinal cells (Hambright et al., 2012) suggest
that the transplanted bolus of cells often remain trapped in clusters
within the subretinal space; however, results from Lamba et al.
(2009) demonstrated integration of human ESC-derived neuro-
retinal cells and the presence of an ERG waveform in the trans-
planted Crx / mouse retina. Poor migration and integration of
cells into the host retina could arise from either the intrinsic
properties of the transplanted donor cells, from host retinal bar-
riers, or more likely, a combination of both. Pioneering work by
Robin Ali’s group suggested that rod photoreceptor precursors
must be isolated at a speciﬁc time in the developing mouse retina
(wP4) if they are to migrate and integrate into the host retina
(MacLaren et al., 2006), although a study from Gust and Reh pro-
posed that adult photoreceptors may also possess these abilities
(Gust and Reh, 2011). In future studies, hiPSC-derived photore-
ceptors must be transplanted at various stages of differentiation todetermine the optimal developmental stage for transplantation. In
addition, proper controls must be utilized to evaluate the effects of
cell replacement. Endogenous reporters may be preferable to viral
cell labelling to eliminate the possibility of viral particle carryover
and potential mislabelling of host cells (West et al., 2012; Gonzalez-
Cordero et al., 2013).
Pearson et al. (2012) published the most deﬁnitive report of
vision restoration to date with cell replacement therapy. In this
study they injected P4eP8 rod precursors into the Gnat/mouse,
which lacks the rod a-transducin required for rod function.
Following cell replacement, the authors showedmorphological and
synaptic integration of the transplanted cells, and functional
scotopic vision rescue through a battery of tests. These tests
included single cell electrophysiology which showed a trans-
planted rod photoreceptor response to light, optical intrinsic im-
aging to demonstrate relay of the visual signal to the visual cortex,
and rescue of an optokinetic response and visually guided behav-
iour. Additionally, a recent study by Gonzalez-Cordero et al. sug-
gested that 3D culture generated mouse ESC-derived
photoreceptors improved integration (Gonzalez-Cordero et al.,
2013), compared to the dearth of integration seen with 2D
methods for photoreceptor production (West et al., 2012). Taken as
a whole, these animal studies highlight the potential for cell based
transplantation therapy. However, whether these results can be
repeated using hiPSC-derived retinal progeny in human patients
remains to be determined.
5. Future directions: transferring hiPSC-derived cell therapy
to clinic, risks and challenges
In order to bring the clinical promise of hiPSCs to realisation a
number of hurdles must ﬁrst be overcome. Tumour formation is
undoubtedly the most serious potential complication associated
with cell replacement therapy from pluripotent stem cell sources.
Great care must be taken prior to transplantation to assure that no
pluripotent cells remain. Tucker et al. used the cell-surface plu-
ripotency marker SSEA1to immunopan for undifferentiated
pluripotent cells prior to the transplantation of mouse iPSC-derived
neuroretinal cells (Tucker et al., 2011). Following two rounds of
SSEA1þ cell depletion, the development of teratomas were elimi-
nated at three weeks post-transplantation. While negative selec-
tion of pluripotent cells is one strategy to minimize tumour risk, an
alternative approach is positive selection for post-mitotic photo-
receptors. Studies using hiPSCs, mouse ESCs, or photoreceptor
precursors obtained from early postnatal mouse retina have used
various sorting methods to enrich for photoreceptors. However,
most studies have sorted photoreceptors using transgenic ﬂuores-
cent protein expression driven by the promoters of photoreceptor
genes such as IRBP, CRX, or NRL (Lakowski et al., 2010; Lamba et al.,
2010; Pearson et al., 2012; Pearson et al., 2010; West et al., 2010;
West et al., 2008), or alternatively have sorted retinal progenitors
earlier in development with RAX (West et al., 2012). While effec-
tive, the use of ﬂuorescent transgenic markers is unlikely to be
suitable for clinical studies. Sorting without reporter insertion
could be potentially feasible with recently identiﬁed cell surface
markers including CD73 alone (Eberle et al., 2011; Koso et al., 2009),
CD73 plus CD24 (Lakowski et al., 2011), or lectins to enrich for
photoreceptors (Balse et al., 2005; Mandai et al., 2010). Even so, it is
currently unclear if these sorting methods would identify other
non-retinal cell types in a mixed population of cells derived from
pluripotent cell sources. For example, CD73 is expressed in
numerous cell types throughout the body, and is also upregulated
in cancerous cells (Zhang, 2010). For these photoreceptor selection
methods to work with pluripotent cell sources, they must either: a)
be tested rigorously for the selection of all other unwanted cell
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starting population of enriched neuroretinal progenitors derived
from hiPSCs. This can be achieved by using a method to enrich for
optic-vesicle like structures, as discussed previously (Meyer et al.,
2011).
The host retina may also create barriers that transplanted cells
must cross, including the outer limiting membrane (OLM) and, not
uncommonly, gliotic scars. The severity of impediment is depen-
dent upon disease type, as well as disease progression. Differences
in disease type and progression on cell transplantation outcome
were systematically evaluated by Barber et al. (Barber et al., 2013).
This study demonstrated the large degree of variability in gliosis
and OLM impediment to cellular integration across six mouse
models of retinal degeneration at different stages of degeneration.
Previous studies transplanting photoreceptor precursors have
attempted to circumvent the physical barriers by pharmacological
treatment with the glial toxin, dl-alpha-aminoadipic acid (West
et al., 2008), or RNAi knockdown of tight junction protein ZO-1
(Barber et al., 2013; Pearson et al., 2010). However, potential un-
toward effects of such treatments, such as disruption of the outer
blood-retinal barrier, may preclude their use in humans. As such,
clinically relevant methods of bypassing the OLM and glial scarring
are still needed to optimise migration and integration of trans-
planted cells into the human retina.
The majority of transplantation studies thus far have focused on
bolus injections of cells, regardless of the cell source. This may be
the easiest method of cell delivery, but transplantation of RPE and
perhaps photoreceptors as sheets on scaffolds or embedded in
biocompatible matrices may be preferable (Diniz et al., 2013).
Establishing polarity in transplanted cells is critical considering the
unique apical and basal functions of both the RPE and photore-
ceptors. In addition, RDDs that arise from RPE defects will likely
require replacement of both RPE and photoreceptors combined.
However, building a combined RPE/photoreceptor scaffold for
transplantation is challenging due in part to the naturally weak
connections between photoreceptor outer segments and interdig-
itating RPE microvilli.
For hiPSC-derived cell transplantation therapy to become a re-
ality, all phases of the generation of retinal cell types must be
performed following current GMP guidelines. To beginwith, hiPSCs
must be generated using non-integrative approaches. This stage
has been assisted by the recent development of a completely
chemically deﬁned and xeno-free method for derivation and
maintenance of pluripotent stem cells (Chen et al., 2011). Themedia
(E8) eliminates many of the reagents in previous pluripotent stem
cell media formulations, including serum albumin, and can be used
in combination with vitronectin coated surfaces for cell adhesion
and growth, eliminating the need for MEF or Matrigel, sources of
animal contaminants. Recent reports have identiﬁed methods for
retinal differentiation of hiPSCs using xeno-free methods. The
combination of new hiPSC derivation protocols with chemically
deﬁned differentiation protocols should enable the realisation
cGMP compliant retinal cells for cell replacement (Sridhar et al.,
2013; Tucker et al., 2013).
HiPSC cells used for autologous cell replacement may hold
certain immunological advantages over generic hESC cells. How-
ever, these cells carry the same genetic mutations as the originator
and are therefore susceptible to the same disease processes as the
host retinal cells. Autologous hiPSC-derived cell transplantation for
the treatment of genetic-based retinal disorders will ﬁrst require
correction of the underlying disease-causing mutation. A number
of techniques are being used for editing genes in hiPSCs. The ﬁrst of
these technologies is zinc ﬁnger nucleases (ZFNs), an artiﬁcial DNA
sequence speciﬁc enzyme that promotes DNA strand breaks at
speciﬁc locations in the genome. The strand break and excisionpromote activation of normal cellular DNA repair processes
including non homologous end joining and homologous repair.
These can be used in combination with speciﬁcally designed plas-
mids used as a template for gene editing. The technology beneﬁts
from relative ease of design, but are expensive and may lead to off
target gene editing. This technology has already been demon-
strated in hiPSCs (Zou et al., 2009). Yusa et al. (2011) showed
restoration of alpha-1 antitrypsin in alpha-1 antitrypsin deﬁcient
cells derived from a patient using ZFNs in combination with piggy-
bacterial artiﬁcial chromosome (BAC) technology.
Recently, a BAC-based vector was used to correct the underlying
disease-causing mutation in the gene encoding ornithine-d-
aminotransferase (OAT), restoring the function of this critical
enzyme in hiPSC-RPE (Howden et al., 2011). A similar but cheaper
technique to ZFNs uses transcription activator-like effector nucle-
ases (TALENs) (Cermak et al., 2011). This technique offers the
beneﬁts of gene editing with the ability to more easily create gene
speciﬁc nucleases. Currently, the costs of such patient speciﬁc cell
development are prohibitive, but it may be possible to generate a
bank of hiPSCs created from a limited number of homozygous HLA-
haplotyped donors that would cover a large proportion of the
population. For example, it has been calculated that 150 selected
homozygous HLA-typed individuals would cover 93% of the pop-
ulation in the UK (Gundry et al., 2012). In the United States, a bank
of only 100 hiPSCs would cover the majority of ethnicities (Euro-
pean American, Asian, Hispanic, and African America) (Gourraud
et al., 2012). However, partial HLA haplotype matching may be
insufﬁcient to stave off immune rejection. In mice, expression of
even minor histocompatibility antigens was enough to elicit acute
rejection of cells differentiated from mouse ES cells (Robertson
et al., 2007). Even so, the inherent immune privilege of ES cell-
derived tissues facilitated the induction of transplantation toler-
ance via minimal host conditioning, leading to long term donor cell
survival (Robertson et al., 2007). Should HLA-matched and/or
autologous hiPSCs exhibit an immunological advantage in humans,
it will need to be determined whether the beneﬁt(s) warrant the
additional labour and expense required for their creation (Okita
et al., 2011; Zhao et al., 2011).
6. Conclusion
HiPSC technology was developed following new understanding
in different ﬁelds of biological science including nuclear transfer
and gene regulation through key transcription factors. Recent
recognition of the importance of this series of breakthroughs was
acknowledged with the awarding of the 2012 Nobel prizes for
medicine and physiology to Sir John Gurdon and Shinya Yamanaka.
As with any new platform the ideal use of the new technology has
taken time to be understood. The alignment of clinical research
with basic scientiﬁc understanding is now beginning to show
considerable promise in bringing clinical translation as has been
demonstrated in this article. At present, the need for dedicated
personnel to reprogram, select and maintain initial colonies of
hiPSCs requires that most research is restricted to large academic
institutions which have a central core stem cell facility. As
reprogramming, differentiation and cell characterisation protocols
continue to improve it is likely that stem cell technology will
become more widely accessible. A further step change that is likely
to make translation easier is the development of industry and
biotechnology collaboration in order to develop large-scale stem
cell production. Together these developments are likely to increase
the availability of hiPSC based technology for the use in investiga-
tive and translational studies in the future. In recent years major
progress has been made in bringing iPS applications to clinical trial
and whilst many challenges remain, the future direction of iPS
S. Borooah et al. / Progress in Retinal and Eye Research 37 (2013) 163e181178development offers the realistic hope of reducing progression and
possibly improving visual function for patients with currently
untreatable retinal diseases.
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